Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (734)	9/28/1998 2:03:00 PM
From: Rocketman	Respond to of 3202

Pfizer to Implement Incyte's Genomic And Microarray Data Management Software Platforms Monday September 28, 8:27 am Eastern Time Company Press Release SOURCE: Incyte Pharmaceuticals Inc. PALO ALTO, Calif., Sept. 28 /PRNewswire/ -- Incyte Pharmaceuticals Inc. (Nasdaq: INCY - news) today announced the expansion of its relationship with Pfizer Inc. (NYSE: PFE - news) to include a license to Incyte's LifeTools(TM) bioinformatics software and LifeArray(TM) microarray data analysis and management software. Pfizer will implement Incyte's LifeTools bioinformatics software and LifeArray microarray data analysis and management software to support its global research efforts. Financial terms of the agreement were not disclosed. The LifeArray software will allow Pfizer researchers to combine Incyte-generated microarray data with microarray data generated from different platforms into one integrated database of gene expression information. The enterprise-wide software is scalable thus enabling Pfizer researchers all over the world to combine and analyze microarray data. The data generated from microarray-based experiments can be integrated and compared with sequence data from the LifeSeq database. ''As costs come down and the use of microarray technology increases, there is a tremendous opportunity in bioinformatics for the management, analysis and integration of the vast amounts of data that can be generated,'' said Roy A. Whitfield, Chief Executive Officer of Incyte. ''By licensing the LifeArray and LifeTools platforms, Pfizer has acquired powerful tools for the management of complex genomic data sets.'' The LifeTools genomic data management system will provide Pfizer researchers with the capability to manage genomic data provided by Incyte as well as from Pfizer's own internal research, track research projects and share data with team members, automate routine tasks, and perform powerful data analyses. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. The Incyte General division develops and markets gene discovery and expression products -- including databases, genomic data management software, microarray-based gene expression services, and related reagents -- enabling the pharmaceutical industry to identify new targets and pathways for drug discovery and development. The Incyte Genetics division will provide databases, bioinformatics, and services relating to sequencing and mapping the human genome and identifying gene sequence variation, enabling the pharmaceutical industry to utilize pharmacogenetics as an integral part of pharmaceutical discovery and development. For more information, visit Incyte's web site at incyte.com. Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 1998. Incyte disclaims any intent or obligation to update these forward-looking statements. SOURCE: Incyte Pharmaceuticals Inc.

To: Mike McFarland who wrote (734)	9/28/1998 2:04:00 PM
From: Rocketman	Read Replies (1) \| Respond to of 3202

Incyte Adopts Stockholder Rights Plan Monday September 28, 8:28 am Eastern Time Company Press Release SOURCE: Incyte Pharmaceuticals Inc. PALO ALTO, Calif., Sept. 28 /PRNewswire/ -- Incyte Pharmaceuticals Inc. (Nasdaq: INCY - news) today announced that its Board of Directors adopted a Stockholder Rights Plan that is designed to strengthen the ability of the Board of Directors to protect Incyte's stockholders and other stakeholders. To implement the plan, Incyte's Board of Directors declared a dividend of one preferred stock purchase right (a ''Right'') for each outstanding share of Incyte Common Stock held of record at the close of business on October 13, 1998. Each Right represents a contingent right to purchase, under certain circumstances, a fractional share of a newly created series of Incyte preferred stock. The Rights would become exercisable and trade independently from Incyte Common Stock upon the public announcement of the acquisition by a person or group of 15 percent or more of Incyte's Common Stock, or ten days after commencement of a tender or exchange offer for Incyte Common Stock that would result in the acquisition of 15 percent or more of Incyte's Common Stock. The Rights expire September 25, 2008 unless redeemed earlier by Incyte's Board of Directors. The Rights can be redeemed by the Board at a price of $0.01 per Right at any time before the Rights become exercisable, but thereafter only in limited circumstances. The Rights distribution will not be taxable to stockholders. The rights plan is designed to protect Incyte stockholders against abusive or coercive takeover tactics and takeover tactics not in the best interests of Incyte and its stockholders, such as acquisitions of control without paying all stockholders a fair premium, coercive tender offers and inadequate offers. It is not intended to prevent an offer that the Board concludes is in the best interests of Incyte and its stockholders. Details of the rights plan will be contained in a letter to be mailed to Incyte's stockholders. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. The Incyte General division develops and markets gene discovery and expression products -- including databases, genomic data management software, microarray-based gene expression services, and related reagents -- enabling the pharmaceutical industry to identify new targets and pathways for drug discovery and development. The Incyte Genetics division will provide databases, bioinformatics, and services relating to sequencing and mapping the human genome and identifying gene sequence variation, enabling the pharmaceutical industry to utilize pharmacogenetics as an integral part of pharmaceutical discovery and development. For more information, visit Incyte's web site at incyte.com. Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 1998. These forward-looking statements speak only as of the date hereof. Incyte disclaims any intent or obligation to update these forward- looking statements. SOURCE: Incyte Pharmaceuticals Inc.